Researchers enrolling patients for study on AI in breast cancer surgery - Aug. 5, 2020
The vast majority of breast cancer patients will undergo surgery as part of their treatment, and most of those patients will choose a lumpectomy to remove the tumor and conserve the breast.
Baylor researchers win AACR Team Science Award - June 23, 2020
The American Association for Cancer Research (AACR) will recognize the founding members and the current project team of the Cancer Genome Atlas (TCGA) project with 2020 AACR Team Science Awards at the AACR Virtual Meeting on June 24.
Resistance to immunosurveillance favors cluster cancer metastasis - June 1, 2020
Clusters of cells seem to have a higher metastatic potential than single cells, and a report published in Nature Cancer shows new insights into what contributes to the clusters’ selective advantage.
New insight into breast cancer resistance to hormone therapy - March 5, 2020
An international team of researchers led by scientists at Baylor College of Medicine has new insights into the function of neurofibromin, a tumor suppressor produced by the NF1 gene.
Molecular roadmap boosts fight against endometrial cancer - Feb. 13, 2020
A study published in Cell provides an unprecedented look at the dozens of molecular steps that occur to bring about endometrial cancer, commonly known as uterine cancer.
Micro-scaled method holds promise for cancer diagnosis - Jan. 27, 2020
Using a using a single-needle biopsy and new technology for tumor diagnosis developed by Baylor College of Medicine and the Broad Institute of MIT and Harvard, researchers have been able to provide a more detailed and wider window into cancer biology than with conventional approaches.
Protein AKAP8 suppresses breast cancer metastasis - Jan. 24, 2020
A protein naturally produced in the body has been found to suppress breast cancer metastasis in animal models of human tumors. Researchers led by Baylor College of Medicine also found that high levels of this protein, AKAP8, predicts a better survival for breast cancer patients.
Mechanism reprograms breast cancer to become metastatic - Dec. 11, 2019
A team led by researchers at Baylor College of Medicine and Harvard Medical School has unveiled a novel mechanism that helps explain how endocrine-resistant breast cancer acquires metastatic behavior, opening the possibility of new therapeutic strategies.
Susan G. Komen® honors Dr. Matthew Ellis with Brinker Award - Oct. 3, 2019
Dr. Matthew Ellis has been awarded the Susan G. Komen® Brinker Award for Scientific Distinction in Clinical Research for his contributions to understanding the genomics of breast cancer and translating this knowledge to the clinic in order to improve the efficacy of breast cancer treatment.
Cell roles in immunotherapy-resistant breast cancer profiled - Aug. 26, 2019
To better understand the specific roles different immune cell types play, a multi-institutional team profiled the immune cell composition of multiple murine models and clinical datasets of triple negative breast cancers.
p53 mutations in cancer patients shed light on gene’s function - July 30, 2019
Researchers at Baylor College of Medicine have conducted a study of TP53 mutations to better understand the processes leading to the inactivation of this important gene.
Colon cancer proteins, genes uncover potential treatments - Apr. 25, 2019
Analyzing both the entire set of genes and all the proteins produced by colon cancer tissues from patient samples has revealed a more comprehensive view of the tumor that points at novel cancer biological mechanisms and possible new therapeutic strategies.
Discovery explains breast cancer cells’ ability to adapt, survive - Jan. 28, 2019
A team led by researchers at Baylor College of Medicine has discovered that breast cancer cells can shift between two forms of the cell surface molecule CD44, CD44s and CD44v.
DPYSL3 an outlier gene in triple-negative breast cancer - Nov. 26, 2018
Researchers have developed an entirely new therapeutic hypothesis on how to treat an aggressive form of triple-negative breast cancer.
Repurposing FDA-approved drugs to fight breast cancer - Nov. 16, 2018
A team of researchers shows Food and Drug Administration (FDA)-approved compounds can stop cancer growth and can potentially lead to the discovery of drugs in a way that is quicker and less expensive than traditional drug development strategies.
Novel strategy may reduce breast cancer bone metastasis - Nov. 12, 2018
Uncovering a novel mechanism that promotes growth of breast cancer bone metastasis has revealed a potential Achilles' heel for these cancer cells.
Dr. Alastair Thompson to lead breast surgical oncology - Oct. 22, 2018
Dr. Alastair Thompson is bringing his expertise Baylor as the new section chief of breast surgery in the Michael E. DeBakey Department of Surgery, Division of Surgical Oncology, and co-director of the Lester and Sue Smith Breast Center.
Grant supports research into racial, ethnic health disparities - Oct. 2, 2018
The National Cancer Institute has awarded $6.3 million dollars Baylor researchers to create new tools to help researchers to better understand the biological causes behind racial and ethnic health disparities in prostate and breast cancers.
Research leads to rare ER+ breast cancer mutations insight - Sept. 4, 2018
Researchers conducted the largest analysis to date to establish associations between rare somatic mutations and prognosis in estrogen receptor positive (ER+) breast cancer.
Estrogen receptor events linked to breast cancer metastasis - Aug. 7, 2018
Researchers identify estrogen receptor alpha gene (ESR1) translocation events that drive not only therapeutic resistance, but also trigger ER+ breast cancer cells to metastasize.
DNA repair defect may drive some cancer treatment resistance - May 25, 2018
Researchers found that defects in selective DNA damage repair pathways can drive endocrine treatment resistance in a subset of estrogen receptor positive breast cancer patients.
New promise found in treating triple negative breast cancer - March 26, 2018
A new study has identified a novel treatment strategy that may be effective for triple negative breast cancer patients.
Dr. Xiang Zhang receives Sue Eccles Young Investigator Award - March 19, 2018
Dr. Xiang Zhang has been named as the 2018 recipient of the Sue Eccles Young Investigator Award from the Metastasis Research Society (MRS).